Announcements Trials
Browse Landscape

Phase

Phase 2 3Phase 1/2 1

Status

Completed 3

Sponsor Class

OTHER 6INDUSTRY 3

Study Type

Interventional 3

Sponsor

Cancer Type

Lymphoid 1Gastrointestinal 1Dermatologic 1

Conditions

Recurrence 1Melanoma 1Lymphoma, Non-Hodgkin 1Lymphoma, Large B-Cell, Diffuse 1Colorectal Neoplasms 1

Interventions

Carboplatin 273Paclitaxel 267Gemcitabine 244Bevacizumab 226Cisplatin 218pembrolizumab 214Docetaxel 210Pemetrexed 162Capecitabine 148Fluorouracil 129Oxaliplatin 121Cyclophosphamide 121Nivolumab 112Dexamethasone 100Trastuzumab 89Leucovorin 87Cetuximab 85Rituximab 83Irinotecan 82Injections 81Erlotinib Hydrochloride 70Prednisone 68Doxorubicin 68Temozolomide 67atezolizumab 65Bortezomib 65Ipilimumab 64Fulvestrant 59Radiotherapy 54Drug Therapy 51

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

3 trials
RecentStart dateEnrollment
Phase 2 × INDUSTRY × pidilizumab × Clear all
NCT01435369 2016-01-21

Safety, Tolerability and Efficacy Study of the Monoclonal Antibody, CT-011, in Patients With Metastatic Melanoma

Medivation, Inc.

Phase 2 Completed
103 enrolled
Dermatologic

Melanoma

NCT00890305 2015-07-08

Study to Evaluate the Safety, Tolerability and Efficacy of FOLFOX + CT-011 Versus FOLFOX Alone

Medivation, Inc.

Phase 2 Completed
171 enrolled
Gastrointestinal

Colorectal Neoplasms

NCT00532259 2014-09-12

CT-011 MAb in DLBCL Patients Following ASCT

CureTech Ltd

Phase 2 Completed
72 enrolled 9 charts
Lymphoid

Lymphoma, Non-Hodgkin, Recurrence, Lymphoma, Large B-Cell, Diffuse

Data powered by HemOnc (CC BY 4.0) Colophon âš¡